Drug Development

Upcoming study results for Bayer's KERENDIA could unlock a new treatment for millions with non-diabetic chronic kidney disease, a vast and underserved group.

The FDA just granted Orphan Drug status to a promising ALS therapy. It's a beacon of hope for patients and a masterclass in biotech strategy.

With positive FDA feedback and an innovative digital trial design, Herantis Pharma's HER-096 moves closer to becoming a potential disease-modifying therapy.

With a seasoned drug developer at the helm, preclinical biotech FundaMental Pharma signals a major push to bring its novel TRD therapy through the clinical gauntlet.

Rakovina Therapeutics reports a dramatic financial recovery, slashing costs while boosting AI-driven R&D, positioning its promising cancer pipeline for growth.

As CEO Richard Francis prepares for a key address, Teva's 'Pivot to Growth' is under the microscope. Can innovation truly outpace its generics legacy?

Researchers have discovered a metabolic 'Achilles' heel' in a rare liver cancer, offering a new treatment path beyond ineffective chemotherapy.

A new drug targeting cancer's 'immortality switch' enters a pivotal trial, offering hope for non-small cell lung cancer patients out of options.

Facing a severe cash crunch, Jasper Therapeutics is exploring a sale or even a shutdown, placing the future of its promising urticaria drug, briquilimab, in limbo.

A novel drug for muscle loss in COPD patients has fully recruited its Phase 2 trial, a major step towards the first-ever treatment for sarcopenia.

A new drug combination delays cancer progression by over a year in advanced prostate cancer, offering new hope against treatment resistance, a new study finds.

New long-term data on pegcetacoplan offers significant hope for patients with rare, debilitating kidney diseases, strengthening Sobi's market position.

Haisco's Cipepofol gains US FDA approval, challenging Propofol with enhanced safety and signaling a new era of Chinese pharmaceutical innovation.

With strong data for volixibat, brelovitug, and LIVMARLI, Mirum (MIRM) de-risks its pipeline and sets the stage for growth. Here's the analysis.

A Canadian company's sublingual tablet could replace injections for popular peptides, just as the FDA considers expanding access for millions of users.

New preclinical data shows Sharp Therapeutics' oral drug candidate could reverse key pathologies of the fatal genetic disorder, offering hope beyond symptom management.

Celebrating two decades of innovation, RadioMedix unveils promising new alpha therapy data for pancreatic cancer at the SNMMI 2026 annual meeting.

A new service from Syncell offers researchers an unprecedented, unbiased view of proteins at the nanoscopic level, aiming to find drug targets hidden in plain sight.

With a new CMO who has a drug approval under his belt, ImmunoGenesis is poised to advance its novel therapy for hard-to-treat 'cold' tumors.

A novel oncolytic bacteria therapy gains key approvals in the US and China, showcasing a new global development model enabled by CDMO Porton Advanced.